TRK 700

Drug Profile

TRK 700

Alternative Names: TRK700

Latest Information Update: 24 Mar 2016

Price : $50

At a glance

  • Originator Toray Industries
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postherpetic neuralgia

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Postherpetic neuralgia (In adults, In the elderly) in Japan (PO)
  • 29 Feb 2016 Clinical trials in Postherpetic neuralgia in Japan (PO)
  • 01 Jan 2016 Toray Industries plans an early phase II trial for Postherpetic neuralgia (In adults, In the elderly) in Japan (PO) (NCT02701374)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top